Skip to content

Taking Brain Monitoring to the Next Level

Taking Brain Monitoring to the Next Level

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04246320
Acronym
HDBRAIN
Enrollment
7
Registered
2020-01-29
Start date
2020-01-30
Completion date
2022-08-13
Last updated
2023-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea, Postoperative Cognitive Dysfunction, Postoperative Delirium

Keywords

goal directed therapy (GDT), magnetic resonance imaging (MRI), neurocognitive testing

Brief summary

This one arm clinical study will assess the impact of a goal directed therapy intervention, aiming at optimizing depth of anesthesia and intraoperative blood pressure on the incidence of postoperative cognitive dysfunction and delirium relative to a standardized anesthetic plan. We will enroll 60 patients and will measure the neurocognitive status (MoCA test) of patients before and after surgery (at discharge, within 2 weeks after surgery and 6 months after surgery) to determine the relative impact of anesthetic care on the development of postoperative delirium and cognitive decline. All patients will have a brain scan (fMRI) before and after surgical intervention. Patients will also be asked to participate in an optional blood draw which will take place during their brain imaging visit and post operatively (within 2 days after surgery).

Detailed description

This study will test the hypothesis that a goal directed therapy intervention, which optimizes depth of anesthesia and intraoperative blood pressure can decrease the incidence of postoperative neurocognitive dysfunction Subjects will be recruited for the study and the protocol explained. In addition to standard American Society of Anesthesiologists (ASA) monitoring, we will monitor continuous non-invasive blood pressure and 4 lead electroencephalogram (EEG) channels. Patients will receive standardized anesthesia care in addition to a goal directed therapy hemodynamic management (MAP \> 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50). Neurocognitive testing: In order to assess general cognitive function, the Montreal Cognitive Assessment test will be used. Cognitive function will be measured preoperatively and postoperatively at discharge, 1 month and 6 months after surgery. For delirium measurement, we will administer daily the Confusion Assessment Method (CAM-ICU) for up to 3 days. The Montreal Cognitive Assessment (MoCA) is a screening tool to assess mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructionals skills, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal. The Wide Range Assessment of Memory and Learning (WRAML2) is a broad-based memory battery that provides a flexible measure of memory functioning and learning and takes approximately 45-60 minutes to administer. This assessment will be conducted at the first MRI visit and at the 6 month follow up. The Confusion Assessment Method for the ICU (CAM-ICU) screens for the development of delirium and assesses four features: 1) acute change or fluctuation in mental status from baseline, 2) inattention, 3) altered level of consciousness, and 4) disorganized thinking. The CAM-ICU is positive, and the patient is considered to have delirium, if features 1 and 2 and either feature 3 or 4 are present. Brain imaging: The timing of pre-operative brain imaging will be as allowed by patient factors and scanner availability, typically less than 15 days before surgery, when the patient comes for the preoperative evaluation, and postoperatively within 2 weeks after surgery. Optional Blood Draws: Patients will be asked to provide 2 optional blood samples, drawn the day of their brain imaging visit and post-operatively (within 2 days). These samples will be used to asses blood inflammatory biomarkers in obstructive sleep apnea (OSA) subjects and non-OSA subjects between baseline and post-surgery.

Interventions

OTHERGoal directed therapy (GDT)

Goal directed therapy (GDT) hemodynamic management (MAP \> 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).

Sponsors

University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 45-75 years old, * undergoing abdominal, orthopedic, gynecological, or urological surgery * expected to stay in hospital for at least 24hours

Exclusion criteria

* Substantial hearing impairment or inability to understand English, since there needs to be neurocognitive testing done * status post craniotomy * severe dementia

Design outcomes

Primary

MeasureTime frameDescription
Postoperative cognitive dysfunctionPreoperatively (within 15 days of surgery)Montreal Cognitive Assessment (MoCA) test
Postoperative DeliriumDaily for up to 3 days postoperativelyConfusion Assessment Method (CAM-ICU)

Secondary

MeasureTime frameDescription
Examining brain changes IIpostoperatively within 2 weeks of surgeryUsing non-invasive magnetic resonance imaging based diffusion tensor imaging
Examining brain changes III6 months post surgeryUsing non-invasive magnetic resonance imaging based diffusion tensor imaging
Examining brain changesTypically less than 15 days before surgery, when the patient comes for the preoperative evaluation, postoperatively at up to 48 hours after surgery, and 6 months post surgeryUsing non-invasive magnetic resonance imaging based diffusion tensor imaging
Blood anti-inflammatory biomarkerspre-operatively (within 15 days before surgery)Assess blood inflammatory biomarkers (Il6, Il10, TNFa, IL1b, HMGB1) in OSA subjects and non-OSA subjects

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026